Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)

Next Previous
X
Search
Trial Profile

A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deucrictibant (Primary)
  • Indications Hereditary angioedema
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CHAPTER-1; HAE CHAPTER-1
  • Sponsors Pharvaris

    • Most Recent Events

    • 05 Sep 2024 According to a Pharvaris media release, data from this study will be presented at the Bradykinin Symposium in Dallas, TX from September 13-14, 2024
    • 28 Aug 2024 According to a Pharvaris media release, data from this study will be presented at the upcoming 7th Bradykinin Symposium, to be held from September 5-6, 2024, in Berlin, Germany.
    • 04 Jun 2024 According to a Pharvaris media release, data from this study presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top